https://arthrosi.com/arthrosi-therapeutics-inc-announces-impressive-phase-2a-study-results-for-gout-patients/ 2021-08-18T13:02:19+00:00 https://arthrosi.com/arthrosis-new-molecule-ar882-for-gout-shows-blockbuster-potential/ 2021-08-18T13:02:36+00:00 https://arthrosi.com/arthrosi-expands-disease-expertise-with-new-board-of-director-appointment/ 2021-08-18T13:02:53+00:00 https://arthrosi.com/arthrosi-establishes-joint-venture-in-china-to-accelerate-development-of-innovative-drug-portfolio/ 2021-10-13T20:27:14+00:00 https://arthrosi.com/arthrosi-appoints-robert-thomas-keenan-md-mph-mba-as-chief-medical-officer/ 2021-10-13T20:29:44+00:00 https://arthrosi.com/arthrosi-presents-ar882-posters-at-acr-2021/ 2021-11-02T16:54:36+00:00 https://arthrosi.com/arthrosi-therapeutics-inc-announces-patient-enrollment-in-global-phase-2b-study-of-ar882/ 2021-12-14T17:33:53+00:00 https://arthrosi.com/arthrosi-welcomes-new-chief-financial-officer/ 2022-02-22T17:52:15+00:00 https://arthrosi.com/arthrosi-completes-ar882-renal-impairment-study/ 2023-08-20T21:25:32+00:00 https://arthrosi.com/arthrosi-completes-ar882-phase-2b-study-enrollment/ 2023-08-20T21:26:10+00:00 https://arthrosi.com/arthrosi-announces-positive-topline-results-for-ar882-phase-2b-study/ 2023-08-20T21:26:40+00:00 https://arthrosi.com/arthrosi-secures-75m-in-series-d-financing/ 2023-08-20T21:27:37+00:00 https://arthrosi.com/arthrosi-therapeutics-ar882-prepares-to-enter-into-global-phase-3-study/ 2023-08-20T21:28:09+00:00 https://arthrosi.com/arthrosi-announces-multiple-presentations-at-the-american-college-of-rheumatology-acr-convergence-2023/ 2023-10-17T16:03:28+00:00 https://arthrosi.com/arthrosi-to-present-positive-phase-2-data-for-its-novel-selective-urat1-inhibitor-ar882-in-patients-with-tophaceous-gout-at-acr-convergence-2023/ 2023-11-08T21:45:34+00:00 https://arthrosi.com/wp-content/uploads/2023/11/Tophi-image.jpg https://arthrosi.com/arthrosi-announces-multiple-presentations-at-the-european-league-against-rheumatism-eular-congress-2024/ 2024-05-31T16:41:13+00:00 https://arthrosi.com/arthrosi-announces-first-patient-dosed-in-pivotal-phase-3-reduce-2-trial-of-lead-compound-ar882/ 2024-07-01T19:43:50+00:00 https://arthrosi.com/arthrosi-therapeutics-receives-fda-fast-track-designation-for-ar882-in-tophaceous-gout/ 2024-12-20T21:55:21+00:00 https://arthrosi.com/arthrosi-therapeutics-surpasses-50-patient-enrollment-in-pivotal-phase-3-reduce-2-trial-of-ar882-in-patients-with-gout-including-those-with-tophaceous-gout/ 2024-12-20T21:57:04+00:00 https://arthrosi.com/arthrosi-therapeutics-completes-enrollment-in-pivotal-phase-3-reduce-2-trial-of-ar882-for-the-treatment-of-gout-and-tophaceous-gout/ 2025-03-05T16:43:36+00:00 https://arthrosi.com/arthrosi-announces-first-patient-dosed-in-replicate-pivotal-phase-3-reduce-1-trial-of-lead-compound-ar882/ 2025-03-17T15:41:53+00:00 https://arthrosi.com/arthrosi-therapeutics-surpasses-50-patient-enrollment-in-replicate-pivotal-phase-3-reduce-1-trial-of-pozdeutinurad-ar882-in-patients-with-gout-including-those-with-tophaceous-gout/ 2025-07-11T14:30:36+00:00 https://arthrosi.com/arthrosi-announces-multiple-presentations-at-the-european-alliance-of-associations-for-rheumatology-eular-congress-2025/ 2025-07-11T14:31:25+00:00 https://arthrosi.com/arthrosi-therapeutics-achieves-full-enrollment-of-the-second-pivotal-phase-3-trial-of-pozdeutinurad-ar882-in-patients-with-gout-including-those-with-tophaceous-gout/ 2025-08-21T21:04:05+00:00 https://arthrosi.com/arthrosi-secures-153-million-in-series-e-financing-to-complete-pivotal-development-of-pozdeutinurad-for-the-treatment-of-gout-and-tophaceous-gout/ 2025-10-14T16:01:28+00:00 https://arthrosi.com/sobi-to-acquire-arthrosi-therapeutics-strengthening-pipeline-for-the-potential-treatment-of-gout/ 2025-12-15T21:01:11+00:00